CUE Cue Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CUE

Price (delayed)

$30.56

Market cap

$123.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.98

Enterprise value

$109.91M

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 38

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the ...

Highlights
The EPS has soared by 74% YoY and by 41% QoQ
The net income has soared by 52% YoY and by 27% from the previous quarter
The company's equity fell by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cuebiopharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CUE

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
13.56%
1 week
34.98%
1 month
2.38%
1 year
64.3%
YTD
233.62%
QTD
342.9%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$32.73M
Gross profit
$32.73M
Operating income
-$19.62M
Net income
-$19.52M
Gross margin
100%
Net margin
-59.6%
Cue Biopharma's operating margin has soared by 88% YoY and by 38% from the previous quarter
CUE's net margin has surged by 88% year-on-year and by 38% since the previous quarter
The net income has soared by 52% YoY and by 27% from the previous quarter
The company's operating income has surged by 52% YoY and by 26% QoQ

Price vs fundamentals

How does CUE's price correlate with its fundamentals

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
4.6
P/S
4.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
The EPS has soared by 74% YoY and by 41% QoQ
The P/B is 84% above the last 4 quarters average of 2.2 and 23% above the 5-year quarterly average of 3.3
The company's equity fell by 18% QoQ
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 41.7 and 21% lower than the last 4 quarters average of 5.0
CUE's revenue is up by 19% since the previous quarter

Efficiency

How efficient is Cue Biopharma business performance
The ROS has soared by 88% YoY and by 39% QoQ
The ROIC has soared by 80% YoY and by 61% QoQ
Cue Biopharma's return on equity has surged by 57% YoY and by 40% QoQ
The ROA has soared by 53% YoY and by 31% from the previous quarter

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
Cue Biopharma's total liabilities has decreased by 41% from the previous quarter and by 41% YoY
The total assets is up by 39% year-on-year but it has declined by 27% since the previous quarter
CUE's debt is 84% smaller than its equity
CUE's debt to equity has shrunk by 85% YoY
CUE's debt has dropped by 52% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.